Vijaya Diagnostic Centre Unaudited Financial Results for Q3 FY2025-26 Approved

The Board of Directors of Vijaya Diagnostic Centre Limited approved the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025. The results reflect strong performance across diagnostic services, especially after the recent amalgamation. Key figures show a rise in total income for both standalone and consolidated results compared to the previous year’s corresponding periods. The review process was completed by statutory auditors, resulting in an unmodified report.

Board Approval of Q3 Financials

Vijaya Diagnostic Centre Limited has announced the outcome of its Board Meeting held on Friday, February 13, 2026. During this meeting, the Board inter-alia considered and approved the Unaudited Standalone and Consolidated Financial Results for the third quarter and the nine months ending December 31, 2025. The Board Meeting commenced at 12:30 P.M. and concluded at 02:30 P.M. (IST).

Standalone Financial Highlights (Q3 FY2025-26 vs Q3 FY2024-25)

The standalone results for the quarter ended December 31, 2025, show total income reaching Rs. 19,862.82 Lakhs, up from Rs. 16,252.14 Lakhs in the corresponding period last year. Profit before tax (excluding exceptional items) stood at Rs. 5,902.78 Lakhs compared to Rs. 4,458.86 Lakhs previously. Profit for the period ended December 31, 2025, was Rs. 4,418.52 Lakhs, an increase from Rs. 3,370.18 Lakhs.

Consolidated Financial Performance (Q3 FY2025-26 vs Q3 FY2024-25)

On a consolidated basis, total income for the quarter ended December 31, 2025, was Rs. 21,031.22 Lakhs, a substantial increase from Rs. 17,367.96 Lakhs in the prior year. Profit before tax and exceptional items was Rs. 5,822.28 Lakhs, up from Rs. 4,670.46 Lakhs. Consolidated Profit for the period was Rs. 4,314.61 Lakhs, compared to Rs. 3,529.89 Lakhs recorded for the quarter ended December 31, 2024.

Amalgamation and Adjustments

A significant factor influencing the comparison is the accounting treatment for the amalgamation of Medinova Diagnostic Services Limited, effective from April 1, 2024. The financial results have been restated for prior periods to reflect this merger using the ‘pooling of interest’ method. Furthermore, the company noted that the statutory auditors have issued an unmodified limited review report on both the standalone and consolidated results.

Other Disclosures

The Board also noted that the company has recognized estimated incremental impact of the new consolidated labor codes based on actuarial valuation, pending final rule notifications. Investors can access the full detailed results on the websites of the respective stock exchanges and the company portal.

Source: BSE

Previous Article

Aarti Pharmalabs Clarification on Delayed Disclosure Event to Exchange

Next Article

Indo Count Industries Limited Unaudited Financial Results for Q3 FY2026